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Background: The objectives of the current study were to determine amikacin pharmacokinetics in patients
undergoing treatment with continuous venovenous haemodiafiltration (CVVHDF) in an Intensive Care Unit (ICU),
and to determine whether peak and trough concentration data could be used to predict pharmacokinetic
parameters. An open prospective study was undertaken, comprising five critically ill patients with sepsis requiring
CVVHDF.
Methods: Peak and trough plasma concentrations and multiple serum levels in a dosage interval were measured
and the latter fitted to both a one- and two-compartment model. Blood and ultrafiltrate samples were collected
and assayed for amikacin to calculate the pharmacokinetic parameters; total body clearance (TBC), elimination rate
constant (k) and volume of distribution (Vd). The concentration of amikacin in ultrafiltrate was used to determine
the clearance via CVVHDF. CVVHDF was performed at prescribed dialysate rates of 1-2l h-1 and ultrafiltration rate of
2l h-1. Blood was pumped at 200ml/min using a Gambro blood pump and Hospal AN69HF haemofilter. Amikacin
dosing was according to routine clinical practice in the Intensive Care Unit.
Results: The multi serum level study indicated that the one compartment model was adequate to characterize the
pharmacokinetics in these patients suggesting that peak and trough plasma level data may be used to estimate
individual patient pharmacokinetic parameters and to optimise individual patient dosing during treatment with
CVVHDF. CVVHDF resulted in an amikacin k of 0.109+/−0.025 h, t1/2 of 6.74 +/− 1.69h, TBC of 3.39+/−0.817 h
-1, and
Vd of 31.4 +/− 3.27. The mean clearance due to CVVHDF of 2.86 l h
-1 is similar to the creatinine clearance of 2.74
+/−0.4 lh-1. Amikacin was significantly cleared by CVVHDF, and its half life in patients on CVVHDF was
approximately 2–3 times that reported in subjects without renal impairment and not undergoing haemodiafiltration
for any reason.
Conclusions: CVVHDF contributes significantly to total clearance of amikacin. The use of pharmacokinetic
parameter estimates obtained from two steady state serum-drug concentrations (peak and trough) can be used to
guide individualised dosing of critically ill patients treated with CVVHDF. This is considered a useful strategy in this
patient cohort, particularly in avoiding the risk of underdosing.
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Aminoglycoside antibiotics are used to treat serious infec-
tions caused by gram negative microorganisms in intensive
care unit (ICU) patients. They are an increasingly popular
choice for both empiric and directed therapy as they are
less likely to engender resistance than quinolones [1] and
have a lesser incidence of promoting Clostridium difficile
infection than other antibiotics [2]. The intersection of
aminoglycoside and continuous veno-venous haemodiafil-
tration (CVVHDF) use is an ever increasing likelihood in
the ICU setting. The use of amikacin in particular is in-
creasing as it may offer a more extensive spectrum of cover
than gentamicin [3], especially with the advent of Extended
Spectrum Beta-Lactamase (ESBL) producing organisms.
Elimination of amikacin is mainly via the renal route.
Its dosage regimens must therefore be adjusted in severe
renal insufficiency to prevent accumulation of the drug
to toxic levels and the associated risk of oto- and
nephrotoxicity. However, this drug’s hydrophilicity and
low molecular weight also make it likely to be cleared by
CVVHDF and consequently pharmacokinetic studies
during CVVHDF are required to optimise dosing regi-
mens and obtain therapeutic concentrations.
In general, data relating toxicity with aminoglycoside con-
centrations refer to trough plasma concentrations [4]. Low
serum peak aminoglycoside concentrations are associated
with an increased risk of clinical failure [5,6] and the emer-
gence of resistant strains [7]. A marked variability in amino-
glycoside pharmacokinetic parameters has been reported in
critically ill patients [8,9]. For example an increased volume
of distribution for aminoglycoside antibiotics has been
found in critically ill patients with sepsis [10] and ascites
[11]. Additionally, augmented renal clearance has been
described in certain patient cohorts, e.g. burns patients.
There are some studies investigating the effects of CVVH
on clearance of amikacin [12-14] but there is little
published evidence describing the effect of CVVHDF.
CVVH depends predominantly on convection alone while
CVVHDF involves a combination of solute clearance by
diffusion and convection, and is generally expected to have
increased removal efficiency over CVVH [15]. One study
has suggested that 40% of an amikacin dose could be
removed by CVVHDF based on a study of six renal failure
patients [16]. Another study recently published investigated
pharmacokinetics of amikacin in patients on CVVHDF suf-
fering from sepsis or septic shock following administration
of a 25 mg/kg loading dose [17]. This study illustrated that
the half life (~6.5 h) of amikacin in these patients on
CVVHDF was much lower than reported for patients with
renal impairment not receiving dialysis [18] (> 30 hours in
anuric patients during the interhemofiltration period).
However it did not determine specifically the contribution
of CVVHDF to amikacin clearance. Furthermore, it was
suggested that accumulation following high loading dosemay be an issue in subsequent doses if the dosage interval
is not adequately extended. A further recent case report of
two patients demonstrated the value of clearance via
CVVHDF when administering high doses of amikacin to
patients with sepsis due to panresistant Pseudomonas
aeruginosa. As this combination was used as a therapeutic
option to enable higher dosing, no pharmacokinetic ana-
lysis was presented in that study [19]. CVVHDF is the pre-
ferred modality of continuous renal replacement therapy in
the hospital setting of the current work.
A 1-compartment model is considered adequate to de-
scribe amikacin pharmacokinetics in most clinical settings
to facilitate aminoglycoside dosage adjustments/calcula-
tions [4], once peak concentrations are measured after a
short distribution phase e.g. 30 minutes after a 30 minute
infusion. In the study by Taccone et al. a 2-compartment
model was used for the pharmacokinetics analysis of ami-
kacin plasma concentrations following the high loading
dose in patients on CVVHDF [17]. Due to the unknown
pharmacokinetic behaviour of amikacin in patients on
CVVHDF, it was desirable to establish whether a 1-
compartment model rather than a 2-compartment model
would still be a suitable model selection in these patients.
Collection and analysis of multiple serum concentration
data is not routine in the clinical setting, therefore assess-
ment of the suitability of the use of peak and trough data
only, to calculate pharmacokinetic parameters is man-
dated. This type of data would be routine in a standard
therapeutic drug monitoring (TDM) scenario.
The practice in the hospital setting of the current
study prior to the commencement of this study was for
the dosage of aminoglycosides to be modified during
CVVHDF, on the basis of the best prescribing recom-
mendations of the time. The levels (peak and trough
values) obtained indicated potential underdosing and
suggested significant CVVHDF induced clearance.
The deficit of data on amikacin pharmacokinetics dur-
ing treatment with CVVHDF, and the evident potential
for underdosing due to clearance via CVVHDF in these
patients prompted this study.
The objectives of the study were:
a) to carry out a prospective study of patients treated
with amikacin and CVVHDF, and to determine amikacin
pharmacokinetic parameters including an estimate of
clearance due to CVVHDF
b) to determine whether a 1-compartment model or a
2-compartment model better fitted multiple serum con-
centration data over the course of one dosage interval in
patients on CVVHDF.
c) to determine whether peak and trough data alone
would be adequate to calculate pharmacokinetic para-
meters and subsequent dose recommendations, as this
data is obtained during routine therapeutic drug moni-
toring (TDM) practice.
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Patient Selection
The decision to treat with CVVHDF and amikacin was
determined prior to the inclusion of the patients in the
study. It was an open, prospective, non-interventional
study. Demographic data and clinical characteristics are
given in Table 1. Estimates of creatinine clearance (CrCl)
were obtained using the method of Jelliffe and Jelliffe [20].
Ethical approval was obtained from the Joint Hospitals
Ethics Committees (St James Hospital/Adelaide and Meath
Hospital Dublin, Incorporating the National Children’s Hos-
pital Ref No. 041007/7704). Approval was obtained from
the Irish Medicines Board. Written informed consent to
participate and publish (predominantly consent by proxy)
was obtained in compliance with Helsinki declaration.
CVVHDF procedure
A 0.6 m2 polyacrilonitrile cylinder haemofilter (Prisma
M100, Preset AN69HF, Hospal, Lyon, France) was utilised.
Blood was pumped through the membrane at a rate of
200 ml min-1. The dialysate fluid passed once across the
membrane into the dialysate compartment of the filter at
a rate of 1–2 l h-1. The ultrafiltration rate and predilution
replacement solution infusion rates were both 2 l h-1.
Administration of amikacin
Multiple doses of amikacin were administered to each
patient. Each dose of amikacin was infused intravenously
over a period of 30 minutes. Blood samples (7 ml) were
taken immediately prior to the administration of a sub-
sequent dose (trough) and 30 minutes after the infusion
was complete (peak).
Additionally, multiple serum concentrations (mini-
mum of seven; at the end of the infusion, and at 1, 2, 5,
8, 12, 18 hours) in a dosage interval were obtained for at
least one dosage interval for each patient.
In the hospital setting of this study, current target peak
and trough plasma concentrations using once-daily dos-
ing (extended interval dosing) are 50–60 mg/L and <5Table 1 Summary of patients’ clinical and demographic data
ID Sex Age Diagnosis In
P1 M 57 Cirrhosis of liver, sepsis, ARF P
P2 F 68 Colonic obstruction, post-op ARF, sepsis P
P3 M 59 ALL with neutropenic sepsis and ARF E
P4 M 63 Ruptured abdominal aortic aneurysm repair
with post-op ARF and sepsis
A
P5 F 70 Pneumonia, ARDS K
Mean 63.4 -
1 Initial/ICU admission value.
2 Creatinine clearance value on day 1 of CVVHDF, prior to commencing CVVHDF th
ARF = Acute renal failure.
ALL = Acute lymphocytic leukaemia.
ARDS = Acute Respiratory Distress Syndrome.mg/L respectively and these criteria are consistent with
literature ranges of approximately 40 - 60 mg/L and <5
mg/L [4,21,22]. It should be noted that the study time
period straddled the hospital’s transition from multiple
daily dosing (7.5 mg kg-1 twice daily, trough <2.5 mg l-1,
peak not greater than 30 mg l-1) to once daily/extended
interval dosing.
Analytical Procedures
Concentrations of amikacin in serum and dialysis efflu-
ent fluid were measured using a TDx analyser (Abbott)
using a fluorescence polarization immunoassay. An ami-
kacin standard concentration curve was constructed
using calibrators (0, 5.0, 10, 20, 30 and 50 mg l-1). Blood
samples were stored at 4°C prior to prompt analysis.
Amikacin clearance by CVVHDF was investigated for
a single dosage interval. The amount of amikacin in each
effluent collection during the dosage interval was calcu-
lated by multiplying the measured effluent concentration
in each effluent sample by the volume of effluent col-
lected over the corresponding time period. Effluent sam-
ples were stored at 4°C pending assay.
Pharmacokinetic analysis
Multiple concentration data over a dosage interval – 1
compartment model
Multiple serum concentrations during one dose interval
were used to determine k, Vd, t1/2 and total body clear-
ance (TBC). k was calculated through fitting of the con-
centration time data to a 1-compartment infusion model
using WinNonlin pharmacokinetic software version 5.2,
(Pharsight Corporation, North Carolina, USA).
Multiple concentration data over a dosage interval - 2
compartment model
It was attempted to fit the concentration-time data from
multiple samples taken over a dosage interval to a 2-
compartment infusion model using WinNonlin version




seudomonas aeruginosa 39 10 7
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mpiric cover for sepsis 24 5 10
cinetobacter baumanni 18 5 13
lebsiella pneumoniae 24 2 11
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Figure 1 Semi-log plot of multiple amikacin serum
concentrations in a dosage interval over time, and (linear fit) for
all patients treated concurrently with amikacin and CVVHDF.
Key: ■ patient 1 ● patient 2 х patient 3 Δ patient 4 □ patient 5.
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compartment model facilitated the calculation of TBC,
V1, k, t1/2 (el), t1/2α, t1/2β and Vss. Vss is the estimated
volume of distribution at steady state. In this case, t1/2(el)
is the elimination half life, comparable to t1/2 for the one
compartment model. In order to calculate initial esti-
mates, the post-infusion concentration data was fitted to
a bi-exponential curve of the form Cpt=A1e
-αt+B1e
-βt,
where Cpt is the plasma concentration at time, t. The
parameters A1 and B1 were then transformed to A and B
using equation 1, where T is the duration of the infusion,
Ci = A or B, Yi = A1 or B1 and λi = α or β [23].
Ci ¼ λiTYieλiT  1 ð1Þ
The relevant pharmacokinetic parameters were then
calculated using the following standard equations:
Aβþ Bα
Aþ B ¼ k21 ð2Þ
k10 ¼ αβk21 ð3Þ
V1 ¼ DoseAþ B ð4Þ
where V1 is the volume of the central compartment.
Peak and trough values
In order to evaluate serum concentration data which
would be available under routine therapeutic drug moni-
toring conditions, individualized pharmacokinetic para-
meters were determined from each patient's peak and
trough serum concentration data using the method of
Sawchuk and Zaske [24]. The half life (t1/2), elimination
rate constant (k), TBC and volume of distribution (Vd)
were calculated as follows:
k ¼ lnCpmax  lnCpmin
 
τ  t1 ð5Þ











k Cpmax  Cpmin1ekT
   ð7Þ
where D is the dose, T is the duration of the infusion
and Cpmin1 is the trough concentration from the previ-
ous dose [24]. In the case of the first dose, the term
Cpmin1e
kT was omitted from Equation 7.TBC ¼ k  Vd ð8Þ
Results
Patient demographics
Three men and two women treated with amikacin
during CVVHDF therapy, ages 57–70 (mean +/− SD:
63.4 +/− 5.6 years) were enrolled in the study. Demo-
graphic data and clinical characteristics are given in
Table 1. All five patients enrolled in the prospective
study had severe renal impairment. Three were anuric
throughout treatment (patients 1, 2, 3) and two patients
were anuric on commencing CVVHDF but became oli-
guric during treatment (day 11 and day 10), at which
time treatment with amikacin had stopped. The average
measured effluent flow rate was 3.5 +/−0.6 l h-1.
The mean APACHE II (Acute Physiology and Chronic
Health Evaluation II) score was 26.6 +/− 7.8. The mean
duration of CVVHDF therapy was 11.0 +/− 2.7 days.
Patients 1–4 were diagnosed with sepsis and two
patients (1 and 4) had concomitant liver and renal
impairment.
Pharmacokinetic results
In total 68 amikacin concentrations were determined,
ranging from 1.8 mg l-1 to 68.3 mg l-1. All samples were
quantifiable.
Measuring multiple serum concentrations over a dosage
interval and fitting to 1- and 2-compartment models
The multiple amikacin serum concentrations sampled in
a dosage interval for each of the five patients are pre-
sented graphically in Figure 1. This post infusion data
was analysed in terms of the 1- and, where possible, 2-
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are summarized in Tables 2 and 3 respectively.
Estimates of the pharmacokinetic parameters, k, t1/2,
TBC and Vd, were initially obtained for each patient on
the basis of a 1-compartment model. The results are
presented in Table 2.
The same amikacin serum concentration time data,
fitted to a 2-compartment model gave estimates of the
pharmacokinetic parameters, k, t1/2(el), t1/2α, t1/2β, V1,
TBC and Vss shown in Table 3. It was not possible to
reasonably fit the data for patients 4 and 5 to a 2-
compartment model. The best fit to a 2-compartment
model was with the data from patient 1 where a short
but clear distribution phase was evident. Nevertheless,
the highest CV% values were associated with the esti-
mates for k21, t1/2α and V2, illustrating the variability
surrounding the fitting of data to the distribution
phase, when it is not very distinct and only captured by
1–2 points. Although the data was fitted to a 2-
compartment model for patients 2 and 3, the standard
residual and CV% values were much higher for all para-
meters, and more so those associated with the distribu-
tion phase and the second compartment. Overall the
relevant pharmacokinetic parameters were similar in
Tables 2–3, when considering the values from the same
patient. Therefore, the current data suggest that, although
it was possible to fit the data to a 2-compartment model
in some cases, parameter estimates were similar to those
obtained with a 1-compartment model. Most importantly,
as can be seen from Figure 1, there was little or no distri-
bution phase evident from the concentration-time pro-
files, further supporting the use of a 1-compartment
model for pharmacokinetic analysis of this data. A short
distribution phase is anticipated with aminoglycoside anti-
biotics, which is generally expected to be complete by 30
minutes after the end of the 30 minute infusion [4].
Therefore, in the case of these patients the distribution
phase was evidently very rapid and of a small magnitudeTable 2 Individual patient estimates of amikacin pharmacokin
obtained from multiple amikacin serum concentrations in a d






Mean +/− 0.116 +/−
s.d. 0.024
Median 0.126
t1/2: half life. Vd: volume of distribution. TBC: Total body clearance. k: elimination ratin comparison with the magnitude and time scale of the
rest of the concentration-time profile.
Estimates of pharmacokinetic parameters and dosage
recommendations using peak and trough data only
Individual patient estimates of amikacin pharmacoki-
netic parameters during treatment with CVVHDF were
obtained from amikacin serum concentration data. Esti-
mates of t1/2, k, Vd, and TBC obtained from peak and
trough values are presented for each patient in Table 4.
Initial doses in patients 1, 2 and 4 were commenced
prior to pharmacokinetic recommendations being avail-
able, according to the then current dosing practice on
the ICU (pre-dating the change in dosing strategy). Sub-
sequently pharmacokinetic parameters calculated for
patients 1 and 2 were similar, and a dosing regime of
1500 mg at intervals of 31–32 hours was recommended.
The initial results from these two patients illustrate the
confusion which can surround “once daily” vs. “extended
interval” dosing. The initial dose (900 mg) in patient 1
was subsequently increased to 1100 mg every 24 hours.
Possibly due to the high Vd observed in this patient, this
dose was not adequate to achieve recommended peak
levels, however the interval of 24 hours contributed to a
degree of accumulation. This dosing schedule did not
achieve target Cpmax concentrations in this patient dur-
ing CVVHDF therapy.
Subsequently, in patient 2, the recommended dose of
1500 mg was prescribed, achieving recommended peak
concentrations. However the interval was not increased
immediately and accumulation was noted. The interval
was increased on day 5 and the rate of accumulation
decreased.
In the case of patient 2, stopping CVVHDF therapy
resulted in a three-fold increase in the amikacin half-life.
Figure 2 shows amikacin serum concentrations over
time for Patient 2. The arrow indicates the point at
which CVVHDF therapy was stopped and a subsequentetic parameters during treatment with CVVHDF,
osage interval fitted to a one-compartment model











e constant. CV%: coefficient of variation. PX (1–5) patients 1–5.
Table 3 Individual patient estimates of amikacin pharmacokinetic parameters during CVVHDF therapy assuming a two
compartment model
ID k (h-1) V1 (l) TBC (l h
-1) T1/2α (h) T1/2β (h) T1/2el (h) Vss (l)
P1B 0.093 25.0 2.32 0.25 8.18 7.45 27.33
P2C 0.131 21.95 2.88 0.035 7.61 5.29 31.5
P3C 0.172 24.31 4.19 0.028 5.29 4.02 31.94
t1/2α: half life of the alpha phase. t1/2β: half life of the beta phase. t1/2el: elimination half life. Vss: volume of distribution at steady state. V1: volume of distribution of
the central compartment. TBC: Total body clearance. k: elimination rate constant. CV%: coefficient of variation. PX (1–5) patients 1–5.
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the significant increase in interval between peak and
trough sampling (53.5 h), the need for a further exten-
sion in dosage interval and decrease in dose due to the
decrease in clearance after CVVHDF was discontinued
is evident from the high trough level.Table 4 Peak and trough concentration data and estimates o
Patient profile Dose Dosage interval Cpmax
(mg) (h) (mg l-1
P1A 900 24 31.3
P1B 900 24 33.8
P1C 1100 24 35.7
Mean
P2A 300 19 7.6
P2B 1500 24 50.2
P2C 1500 24 48.5
P2D 1500 29 49.4
P2E 1500 32 55.9
P2F 1500 29 53.8
Mean
CVVHDF Stopped P2G 1500 53.5 68.3
P3A 1500 24 44.9
P3B 1500 24 42.4
P3C 1500 24 46.5
Mean
P4A 600 12 16.2
P4B 600 12 23.4
Mean
P5A 1500 24 48.2
P5B 1500 25 52.4
P5C 1500 28 54.4





* Excluding profile P2G.
Cpmax: maximum serum concentration Cpmin: minimum serum concentration.
t1/2: half life. Vd: volume of distribution. TBC: Total body clearance. k: elimination rat
PX (1–5): patients 1–5. PXA-PXE: first (A) to fifth (E) dosing interval during which serFor patient 3, a 1500 mg dose achieved adequate Cpmax
concentrations, while the Cpmin concentrations were also
below the target threshold with a dosage interval of 24
hours. The mean clearance estimate, 4.4 +/− 0.51 l h-1,
was high and this value was close to the mean observed
effluent flow rate during CVVHDF (4.1 l h-1).f amikacin pharmacokinetic parameters
Cpmin t1/2 k TBC Vd
) (mg l-1) (h) (h-1) (l h-1) (l)
3 6.80 0.102 2.858 28.03
4 7.63 0.091 2.583 28.44
6.2 9.10 0.076 2.579 33.89
7.84 0.090 2.674 30.12
1.8 8.66 0.080 3.096 38.69
2.8 5.52 0.125 3.761 29.97
5.4 7.42 0.093 2.987 31.98
5 8.47 0.082 2.719 33.24
6.1 9.70 0.071 2.062 28.85
7 9.51 0.073 2.239 30.74
8.21 0.088 2.811 32.25
16.1 25.18 0.028 0.668 24.26
2.8 5.74 0.121 3.911 32.42
1.9 5.13 0.135 4.923 36.46
2.1 5.26 0.132 4.278 32.46
5.38 0.129 4.371 33.78
4 5.45 0.127 4.563 35.88
5 5.16 0.134 3.961 29.52
5.31 0.131 4.262 32.70
2.1 5.09 0.136 4.099 30.08
2.4 5.39 0.128 3.701 28.81
2.5 5.29 0.131 3.649 27.84
2.5 6.03 0.115 3.137 27.28
5.45 0.128 3.646 28.50
6.74 0.109 3.39 31.4
1.69 0.025 0.82 3.27
5.88 0.118 3.39 30.4
e constant.
um concentration data was collected for patient PX.
Figure 2 Amikacin serum concentration-time data for Patient P2. The arrow indicates the point at which CVVHDF was ceased. The shaded
areas indicate the target therapeutic peak and trough ranges.
Figure 3 Amikacin serum concentration time data for Patient
P5. The shaded areas indicate the target therapeutic peak and
trough ranges.
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straddled the period of transition from multiple daily
dosing to extended interval dosing of aminoglycosides.
In the case of patient 4, Acetinobacter baumanni was
isolated from sputum samples and amikacin therapy was
initiated. Instead of administering a high dose at
extended interval, 600mg amikacin was administered
twice daily. The Cpmax concentration achieved by the
600 mg dose was 16.2 mg/L and the Cpmin concentration
was 4 mg l-1, which is above the recommended trough
level. If the patient had continued on amikacin following
the second dose, an extended interval should have been
considered due to the decrease in clearance and higher
than recommended trough values.
For patient 5, a dosing schedule of 1500 mg once daily
achieved effective Cpmax concentrations, based on a tar-
get Cpmax/MIC ratio of 10. The MIC for the sensitive
microorganism was 5ug ml-1 amikacin. For profiles C
and D, the dosage interval was extended somewhat to
avoid excessively high Cpmin concentrations. Serum
concentration-time data for this patient, illustrating the
dosing regime accomplishing target concentrations, is
depicted in Figure 3.
The estimates of pharmacokinetic parameters from the
1-compartment model, obtained from the multiple ami-
kacin serum concentration versus time data, can also be
compared with pharmacokinetic parameters estimates
(TBC, Vd, k) obtained from typical TDM data (Sawchuk
and Zaske method) from the same patient profiles. It is
clear that values calculated using both methods for each
patient are similar (Tables 2 and 4). The data from this
study therefore supports the usefulness of the Sawchuk
and Zaske method to obtain appropriate amikacin PK
parameters for patients on CVVHDF. These parameters
are suitable for dosage regimen calculation/adjustment,thereby supporting a practical approach of individualis-
ing amikacin dosing based on routinely available troughs
and peaks in patients on CVVHDF.
Amikacin Clearance due to CVVHDF
Details of amikacin and creatinine clearances obtained
during CVVHDF, together with the CVVHDF conditions
employed are given in Table 5. The mean clearance of
amikacin by CVVHDF was 2.86 +/− 0.41 l h-1, ~89% of
the mean total body clearance for these patient profiles.
The sieving coefficient for amikacin was 0.83 +/− 0.05,
which was consistent with that previously reported in
the literature (0.93 +/− 0.16), although different filters
and CRRT conditions were in use [13]. The observed
sieving coefficient was similar to the unbound fraction
of amikacin, assuming a fraction unbound of 0.8 based
on the fact that 20% or less of amikacin is bound to
Table 5 Clearance of amikacin and creatinine by CVVHDF and summary of CVVHDF conditions
Patient profile ClCVVHDF (l h
-1) FCVVHDF CrCl (l h
-1) Actual effluent flow rate (l h-1) Number. of filters ^ Age of filter* (h)
P1C 2.53 0.98 2.19 3.16 1 16
P2D 2.55 0.94 2.70 2.91 1 27
P3A 3.40 0.87 3.20 4.10 1 1
P5B 2.97 0.80 2.86 3.95 1 26
Mean 2.86 0.90 2.74 3.53 1 -
+/− +/− +/− +/− +/−
s.d. 0.412 0.08 0.42 0.584
*At start of dosage interval.
^ During dosage interval.
PX (1–5) patients 1–5. ClCVVHDF: clearance via CVVHDF FCVVHDF: Fraction of total body clearance via CVVHDF. CrCl: Creatinine clearance.
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CVVHDF estimated using the sieving coefficient, 2.93 l
h-1, was similar to the actual measured clearance (2.86 l
h-1). Creatinine clearance (2.74 +/− 0.42 l h-1) by the fil-
ter was similar to amikacin clearance. The sieving coeffi-
cient for creatinine was 0.80 +/− 0.1. This value was
very close to the sieving coefficient for amikacin, but
was slightly lower and more variable.Discussion
CVVHDF was observed to increase amikacin clearance,
with a mean TBC value of 3.39 l h-1. The results demon-
strate that CVVHDF is capable of significant amikacin
clearance, accounting for most of the measured TBC in
all patients. As such, the CVVHDF status of a patient, i.
e. whether CVVHDF is commenced, temporarily inter-
rupted or discontinued, is of primary importance when
estimating the dose regimen.
The mean half-life during CVVHDF therapy was 6.74
hours, and the median half-life estimate of 5.88 h com-
paring well with that of 6.5 h reported by Taccone et al.
[17] Additionally, the mean elimination rate constant
was 0.109 h-1 indicating that elimination is ~ one third
that observed in subjects with normal renal function. In
patients with normal renal function, the half-life is 2–3
hours but in anephric patients, the half-life increases to
30–60 hours [4]. A wide range of values for the Vd of
aminoglycosides (0.1 to 0.5 l kg-1 ~ 7–35 l)) has been
reported and the observed mean value from the current
study (31.4 +/− 3.27 l) lies at the higher end of this range
(based on Ideal Body Weight (IBW)). Assuming a 70 kg
patient weight, this corresponds to a value of 0.45 l kg-1,
which is comparable to the estimate of Vss of 0.5 l kg
-1
determined by Taccone et al. [17]. Interestingly, the
value for V1 reported in that study was lower (median
0.29 l kg-1) than estimated in the current work; however
it ranged from 0.21-0.62 l kg.
A large volume of distribution in critically ill patients
is not unexpected as sepsis [10], total parenteralnutrition and factors associated with critical illness such
as aggressive fluid therapy and hypoalbuminemia have
been associated with an increased volume of distribution
for aminoglycoside antibiotics [25]. As a result of this
increased volume of distribution and the fact that ami-
noglycosides demonstrate concentration dependent kill-
ing, higher loading doses may be required to obtain
clinically relevant peak concentration values, as is occur-
ring in practice [17].
‘Once-daily’ aminoglycoside dosing is more correctly
described as extended-interval dosing and extension of
the dosage far beyond 24 hours will be required in some
patients with renal dysfunction. The importance of ac-
knowledging this concept, rather than attempting to
maintain a rigid ‘once-daily’ dosage interval, is illustrated
in the cases of patients 1 and 2. In the treatment of the
first patient, where strict ‘once-daily’ dosing was applied,
lower doses at 24-hour intervals failed to achieve target
peak concentrations. The high Vd combined with a lower
dose in patient 1 contributed to the peak concentration
failing to reach the recommended target value. The risk
of accumulation following higher doses to achieve ap-
propriate peak concentrations has also been highlighted
by Taccone et al. [17], and evidence is provided in the
current work to support this concern, where accumula-
tion was evident in patients 1 and 2. However, in con-
trast to patient 1, in the case of patient 2, use of the
recommended dose and extension of the dosage interval
beyond 24 hours, allowed target peak serum concentra-
tions to be achieved, while limiting accumulation. Esti-
mates of amikacin pharmacokinetic parameters were
similar for both patients and the dosage recommenda-
tion for patient 2 was 1500 mg every 32 hours. It is im-
perative that clinicians be aware of the significant impact
of CVVHDF on amikacin clearance and thus the effect of
stopping, interrupting or changing dialysis modality on
amikacin serum concentrations. The observed effect of
stopping CVVHDF was evident in patient 2 (Figure 2).
This study supports the approach of using routinely
measured (both peak and trough) amikacin serum levels
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guiding dosage regimens. For each patient the values of
the pharmacokinetic parameters calculated from peak
and trough data were similar to those calculated from
multiple serum concentration data within a dosing inter-
val fitted to a 1-compartment model. As obtaining mul-
tiple serum concentrations within a dosing interval
would not be practical in the routine clinical setting, a
standard TDM approach of using peak and trough data
only is shown to be suitable for obtaining ongoing
meaningful individual pharmacokinetic data. Use of
regularly obtained peak and trough data to assess indi-
vidual pharmacokinetic parameters is likely to be par-
ticularly valuable in the context of critically ill patients
receiving CRRT. This is due to the complex interaction
between the patient, drug factors and CRRT factors in
influencing drug pharmacokinetics.
Careful consideration should be given to the import-
ance of the timing of the peak and trough sampling. Al-
though several of the profiles in the current work had
no discernible distribution phase, the peak sample
should be taken approximately 30 minutes after the end
of the infusion [4]. It has been suggested that in some
cases a longer distribution phase may be present [4]. In
any case, consideration should always be given to the
timing of the peak sample data used to generate the tar-
get peak range used. Furthermore, trough samples
should be taken 2–4 half lives after the peak sample [4].
In addition, caution must be applied in the interpret-
ation of drug serum levels when interruptions in
CVVHDF therapy have occurred, for example due to fil-
ter clotting or medical interventions.
It has been suggested that the reduced amikacin half life
observed in the study by Robert et al. [12], of patients re-
ceiving CVVH, compared to that reported by Armendariz
et al. [13] arose because of the higher haemofiltration rate
contributing to the higher observed clearance of amikacin.
Furthermore, the longer observed half life during CVVH
compared with CVVHDF is consistent with an increased
dialysis efficiency from CVVHDF in comparison with
CVVH [15]. Therefore it would be anticipated that shorter
half lives would be observed in patients undergoing
CVVHDF in comparison with those observed in patients
undergoing CVVH, as demonstrated by the current study.
These differences in observed half lives underline the rele-
vance of continuous renal replacement therapy mode
employed and conditions used (e.g. flow rate) when con-
sidering potential for drug clearance during dialysis. In
addition to the study by Taccone et al. [17], at present, the
authors are aware of only one other prospective analysis
of amikacin pharmacokinetics in patients undergoing
CVVHDF. That study reported a mean half life of 11.3 h
(+/− 1.5) [16] which is longer than that determined in the
current study. This is likely explained by higher blood flowrates (100 ml min-1 vs. 200 ml min-1 in the current study),
dialysate flow rates and pre-dilution replacement flow
rates (1 l h-1 vs lh-1 to 2 lh-1 in the current study). Al-
though both the current study and that by Moon et al.
[16] found evidence of significant amikacin clearance via
CVVHDF, the differences in calculated pharmacokinetic
parameters further illustrate the effect of CVVHDF condi-
tions employed on amikacin clearance. On the other hand,
no correlation was found by Taccone et al. between
CVVHDF conditions employed and calculated clearance
or trough levels within the range of conditions employed.
The observed clearance values [17] were thought to be
affected by residual renal function and/or potential filter
absorbance. Due to this lack of clarity, a more comprehen-
sive study of CVVHDF parameters employed and amika-
cin levels is warranted to ascertain the effect of CVVHDF
conditions employed on amikacin clearance.
It has been recommended recently that more aggres-
sive dosing practices need to be employed for patients
undergoing dialysis who are treated with aminoglyco-
sides, as poorer outcomes were observed retrospectively
among dialysis patients receiving aminoglycosides, with
one of the risk factors for mortality being lower peak
concentrations relative to MIC [26]. Recently CVVHDF
was employed to enable use of high amikacin doses to
achieve appropriate peak levels while avoiding nephro-
toxicity [19]. This approach should contribute to preven-
tion of treatment failure and minimisation of the
emergence of resistance. This illustrates that there is a
growing acceptance of both the high peak levels of ami-
noglycosides required in many cases along with the po-
tential for significant clearance via CVVHDF. However,
to date data have been lacking to support initial dosage
regimen estimates and the expected range of individual
pharmacokinetic parameters for amikacin in critically ill
patients on CVVHDF.
Limitations of the current study
The limited patient number (5) in this study, together
with their heterogeneity, limits in-depth statistical ana-
lysis of the data. The results are presented as the ranges
and absolute values which might be expected from 5
critically ill patients undergoing CVVHDF.
Conclusions
CVVHDF contributes significantly to total clearance of
amikacin. The use of pharmacokinetic parameter esti-
mates obtained from two appropriately timed steady
state serum-drug concentrations (peak and trough) can
be used to guide individualised dosing of critically ill
patients treated with CVVHDF. This is considered a
useful monitoring strategy particularly in avoiding the
risk of underdosing. The potential for underdosing
coupled with the notable decrease in clearance when
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dosing of patients treated with CVVHDF using estimates
of pharmacokinetic parameters is required.
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